Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Teclistamab in Relapsed or Refractory Multiple Myeloma
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experience
